Latest Market News

Regener8 Resources has formalised its acquisition of the Srebrenica North polymetallic project in Bosnia and Herzegovina, setting the stage for a maiden exploration program targeting high-grade silver and base metals in a prolific European mining district.

Paladin Energy Ltd (ASX:PDN) swung to a quarterly profit with US$8.4 million gross profit and bolstered its balance sheet through a A$400 million equity raise, positioning itself for expansion in uranium production and development.

Titomic Limited is set to shift its corporate domicile from Australia to the United States through a scheme of arrangement, aiming to deepen its US defense market presence and access broader capital pools while maintaining its ASX listing.

Elevra Lithium has raised A$275 million through a fully underwritten institutional placement to fund its North American Lithium expansion and Moblan project development, supported by strong institutional demand.

Nexsen has secured a strategic partnership with GHK Hospital Limited in Hong Kong, marking a significant step in validating and commercialising its rapid point-of-care diagnostics across North Asia.

Li-S Energy has secured vital approvals to airfreight lithium-sulfur prototype cells to the United States, paving the way for direct engagement with US defence and drone sectors.

Element 25 is making steady progress on its Butcherbird Expansion Project in Western Australia, with major equipment ordered, key contracts nearing finalisation, and project financing advancing toward closure ahead of a Q1 2027 commissioning target.

Temple & Webster has delivered its most profitable April ever with EBITDA hitting around $2.5 million, setting the stage for a near doubling of earnings in FY27 despite weak consumer confidence.

Equus Energy’s Pre-FEED study confirms the technical and commercial viability of its North West Shelf gas project, leveraging existing infrastructure to reduce costs and execution risks while targeting both LNG export and WA domestic gas markets.

Anteris Technologies reported a $22.9 million net loss in Q1 2026 but bolstered its cash position to $283 million following a $320 million capital raise. The company is scaling manufacturing and clinical activities for its DurAVR transcatheter heart valve, with US patient enrolment now underway in the pivotal PARADIGM Trial.

Accent Group has laid out an ambitious Vision 2030 strategy aiming for $1.9 billion in sales and a 9%+ EBIT margin. Central to this plan is the expansion of Sports Direct stores and a focus on operational efficiencies and brand evolution.

Aristocrat Leisure delivered a strong half-year profit surge with 16% growth in normalised NPATA on a constant currency basis, driven by market share gains and strategic investments, while declaring a 50c interim dividend.